Search

Your search keyword '"Patil, Vikas"' showing total 9 results
Start Over Author "Patil, Vikas" Journal blood
9 results on '"Patil, Vikas"'

3. Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Author

Chien, Hsu-Chih, primary, Patil, Vikas, additional, Rasmussen, Kelli M, additional, Yong, Christina, additional, Biondo, Juliana M L, additional, Halloran, Mary, additional, Shapouri, Sheila, additional, Wu, Mei, additional, Burningham, Zachary R, additional, Sauer, Brian C, additional, and Halwani, Ahmad S, additional

Published
2019
Full Text
View/download PDF

5. Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse

Author

Halwani, Ahmad S, primary, Chien, Hsu-Chih, additional, Morreall, Deborah Kay, additional, Patil, Vikas, additional, Rasmussen, Kelli M, additional, Li, Catherine, additional, Burningham, Zachary R, additional, Masaquel, Anthony S, additional, Halloran, Mary, additional, Delong-Sieg, Elisha, additional, Schulz, Mathias, additional, Li, Jia, additional, and Sauer, Brian C, additional

Published
2019
Full Text
View/download PDF

7. Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

Author

Halwani, Ahmad S, primary, Rasmussen, Kelli M, additional, Patil, Vikas, additional, Li, Catherine, additional, Young, Christina, additional, Burningham, Zachary, additional, Schulz, Mathias, additional, Li, Jia, additional, Masaquel, Anthony, additional, Halloran, Mary, additional, Delong-Sieg, Elisha, additional, and Sauer, Brian C, additional

Published
2018
Full Text
View/download PDF

9. Incidence of Atrial Fibrillation and Bleeding in CLL Patients Treated with Ibrutinib: Evidence from the Veterans Health Administration

Author

Halwani, Ahmad S., Rasmussen, Kelli, Patil, Vikas, Burningham, Zachary, and Sauer, Brian C

Abstract

Background:Chronic Lymphocytic Leukemia (CLL) is the second most common type of leukemia in adults, with an estimated 62,130 new cases expected to be diagnosed in 2017 (Siegel, Miller, and Jemal 2017). The introduction of novel oral agents in CLL, starting with ibrutinib (IB) in 2013, has revolutionized the therapeutic landscape, with efficacy and safety that compare favorably overall with prior mainstays of treatment such as chemoimmunotherapy. However, novel agents are associated with specific toxicities that may limit their utility. Several clinical trials have suggested that there is an association between IB and the risk of bleeding-related adverse events and atrial fibrillation (Afib) in CLL patients (Leong et al. 2016; McMullen et al. 2014; Lipsky et al. 2015). The risk of bleeding and Afib in CLL patients treated with IB in a real-world clinical setting is unknown.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results